{"relation": [["", "Number of Participants [units: participants]", "Age [units: Years] Mean (Standard Deviation)", "Gender [units: Participants]", "Female", "Male", "Race/Ethnicity, Customized [units: participants]", "African American/African Heritage", "American Indian or Alaskan Native", "Asian - Central/South Asian Heritage", "Asian - East Asian Heritage", "Asian - Japanese Heritage", "Asian - South East Asian Heritage", "Native Hawaiian or Other Pacific Islander", "White - Arabic/North African Heritage", "White - White/Caucasian/European Heritage", "Mixed Race", "Number of participants with the indicated baseline HIV-RNA level [1] [units: participants]", "HIV-1 RNA <100,000", "HIV-1 RNA 100,000-<250,000", "HIV-1 RNA 250,000-<500,000", "HIV-1 RNA >=500,000", "Number of participants with the indicated Baseline CD4+ Cell Count [2] [units: participants]", "CD4+ cells <50", "CD4+ cells 50-<200", "CD4+ cells >=200", "Number of participants with the indicated Center for Disease Control (CDC) Classification [3] [units: participants]", "Asymptomatic HIV Infection", "Symptomatic (non-AIDS) condition", "AIDS", "Median Baseline CD4+ Cell Count [units: cells per cubic millimeter] Median (Full Range)", "Median Baseline HIV-1 RNA Level [units: log10 copies/ml] Median (Full Range)"], ["ABC/3TC + ATV/r", "515", "38.3 (10.03)", "", "86", "429", "", "167", "9", "4", "3", "1", "3", "1", "5", "316", "6", "", "227", "143", "73", "72", "", "69", "190", "256", "", "353", "97", "65", "199 (19 to 754)", "5.076 (2.989 to 6.620)"]], "pageTitle": "Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection - Study Results - ClinicalTrials.gov", "title": "", "url": "https://clinicaltrials.gov/ct2/show/results/NCT00440947?sect=X01&view=results", "hasHeader": true, "headerPosition": "FIRST_ROW", "tableType": "RELATION", "tableNum": 10, "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042988317.67/warc/CC-MAIN-20150728002308-00342-ip-10-236-191-2.ec2.internal.warc.gz", "recordEndOffset": 862088691, "recordOffset": 862075948, "tableOrientation": "HORIZONTAL", "textBeforeTable": "Period 1: \u00a0 36-Week Induction Phase Participant Flow for 3 periods Continuation of ABC/3TC FDC tablet administered QD for an additional 60 weeks in combination with ATV/r QD ABC/3TC + ATV/r: Extension Phase Simplification regimen of the ABC/3TC FDC tablet administered QD for an additional 60 weeks in combination with ATV QD ABC/3TC + ATV: Extension Phase Continuation of ABC/3TC FDC tablet administered QD for an additional 48 weeks in combination with ATV/r QD ABC/3TC + ATV/r: Randomization Phase Simplification regimen of the ABC/3TC FDC tablet administered QD for an additional 48 weeks in combination with 400 mg ATV QD ABC/3TC + ATV: Randomization Phase Abacavir (ABC) 600 milligrams (mg)/lamivudine (3TC) 300 mg fixed-dose combination tablet (FDC) once a day (QD) plus atazanavir (ATV) 300 mg QD + ritonavir (/r) 100 mg QD during the first 36 weeks of the study (planned interim analysis) ABC/3TC + ATV/r: Induction Phase Description \u00a0 Reporting Groups The study had a 36-week", "textAfterTable": "[1] 23 PAR without confirmed HIV-RNA<50c/mL prior to Wk 36 couldn\u2019t be randomized but weren\u2019t withdrawn. Period 2: \u00a0 48-Week Randomization Phase \u00a0 \u00a0 ABC/3TC + ATV/r: Induction Phase \u00a0 \u00a0 ABC/3TC + ATV: Randomization Phase \u00a0 \u00a0 ABC/3TC + ATV/r: Randomization Phase \u00a0 \u00a0 ABC/3TC + ATV: Extension Phase \u00a0 \u00a0 ABC/3TC + ATV/r: Extension Phase \u00a0 STARTED \u00a0 \u00a0 0 \u00a0 \u00a0 210 \u00a0 \u00a0 209 \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0 COMPLETED \u00a0 \u00a0 0 \u00a0 \u00a0 194 \u00a0 \u00a0 185 \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0 NOT COMPLETED \u00a0", "hasKeyColumn": true, "keyColumnIndex": 0, "headerRowIndex": 0}